ArticlePharmaceuticals (Basel, Switzerland)2023

Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients.

Chin-Hsiao TsengPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.